Lowe’s (LOW) Buy Rating Kept by Credit Suisse; With $116.0 Target; Clovis Oncology Has 1.44 Sentiment

January 16, 2018 - By Kurt Siggers

Among 33 analysts covering Lowe’s Companies Inc. (NYSE:LOW), 19 have Buy rating, 1 Sell and 13 Hold. Therefore 58% are positive. Lowe’s Companies Inc. has $120.0 highest and $66 lowest target. $89.46’s average target is -11.30% below currents $100.86 stock price. Lowe’s Companies Inc. had 76 analyst reports since August 19, 2015 according to SRatingsIntel. Piper Jaffray maintained Lowe's Companies, Inc. (NYSE:LOW) on Wednesday, August 23 with “Hold” rating. The stock of Lowe's Companies, Inc. (NYSE:LOW) has “Outperform” rating given on Thursday, August 24 by Credit Suisse. Cantor Fitzgerald maintained the shares of LOW in report on Wednesday, August 19 with “Hold” rating. The stock of Lowe's Companies, Inc. (NYSE:LOW) has “Buy” rating given on Thursday, August 20 by Argus Research. RBC Capital Markets maintained Lowe's Companies, Inc. (NYSE:LOW) rating on Thursday, November 19. RBC Capital Markets has “Outperform” rating and $83 target. The stock has “Buy” rating by Barclays Capital on Friday, January 5. The stock of Lowe's Companies, Inc. (NYSE:LOW) has “Buy” rating given on Wednesday, August 23 by RBC Capital Markets. The rating was downgraded by PiperJaffray to “Neutral” on Monday, October 31. The stock of Lowe's Companies, Inc. (NYSE:LOW) has “Buy” rating given on Wednesday, April 6 by Goldman Sachs. On Thursday, December 8 the stock rating was maintained by RBC Capital Markets with “Outperform”.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has market cap of $2.89 billion. The Company’s commercial product includes Rubraca tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. It currently has negative earnings. The firm is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications.

Since January 1, 0001, it had 0 insider purchases, and 6 sales for $2.61 million activity.

Analysts await Clovis Oncology, Inc. (NASDAQ:CLVS) to report earnings on February, 28. They expect $-1.27 earnings per share, up 30.60% or $0.56 from last year’s $-1.83 per share. After $-1.24 actual earnings per share reported by Clovis Oncology, Inc. for the previous quarter, Wall Street now forecasts 2.42% negative EPS growth.

Palo Alto Investors Llc holds 11.56% of its portfolio in Clovis Oncology, Inc. for 3.33 million shares. Venbio Select Advisor Llc owns 785,700 shares or 5.02% of their US portfolio. Moreover, Redmile Group Llc has 4.05% invested in the company for 996,610 shares. The New York-based Iguana Healthcare Management Llc has invested 3.68% in the stock. Sectoral Asset Management Inc, a Quebec – Canada-based fund reported 251,699 shares.

Ratings analysis reveals 67% of Clovis Oncology’s analysts are positive. Out of 9 Wall Street analysts rating Clovis Oncology, 6 give it “Buy”, 1 “Sell” rating, while 2 recommend “Hold”. The lowest target is $15.0 while the high is $74.0. The stock’s average target of $42.67 is -27.69% below today’s ($59.01) share price. CLVS was included in 9 notes of analysts from August 24, 2016. Morgan Stanley initiated the stock with “Overweight” rating in Friday, January 13 report. The firm has “Buy” rating by Bank of America given on Friday, January 27. The stock has “Outperform” rating by Credit Suisse on Wednesday, September 21. Chardan Capital Markets initiated it with “Sell” rating and $15.0 target in Tuesday, October 25 report. Stifel Nicolaus maintained Clovis Oncology, Inc. (NASDAQ:CLVS) on Wednesday, September 21 with “Buy” rating. On Wednesday, August 24 the stock rating was maintained by Mizuho with “Neutral”. The firm has “Buy” rating by SunTrust given on Friday, September 23. The company was upgraded on Thursday, January 26 by Piper Jaffray. The firm earned “Hold” rating on Wednesday, December 21 by WallachBeth Capital.

The stock decreased 1.54% or $0.92 during the last trading session, reaching $59.01. About 1.52 million shares traded or 26.82% up from the average. Clovis Oncology, Inc. (CLVS) has risen 282.71% since January 16, 2017 and is uptrending. It has outperformed by 266.01% the S&P500.

LoweÂ’s Companies, Inc. operates as a home improvement firm in the United States, Canada, and Mexico. The company has market cap of $83.69 billion. It offers a line of products for maintenance, repair, remodeling, and decorating. It has a 24.31 P/E ratio. The firm provides home improvement products in various categories, such as lumber and building materials, tools and hardware, appliances, fashion fixtures, rough plumbing and electrical, seasonal living, lawn and garden, paint, millwork, flooring, kitchens, outdoor power equipment, and home fashions.

Analysts await Lowe's Companies, Inc. (NYSE:LOW) to report earnings on March, 7. They expect $0.86 EPS, 0.00% or $0.00 from last year’s $0.86 per share. LOW’s profit will be $713.60 million for 29.32 P/E if the $0.86 EPS becomes a reality. After $1.05 actual EPS reported by Lowe's Companies, Inc. for the previous quarter, Wall Street now forecasts -18.10% negative EPS growth.

Investors sentiment increased to 1.04 in 2017 Q3. Its up 0.01, from 1.03 in 2017Q2. It is positive, as 76 investors sold Lowe's Companies, Inc. shares while 406 reduced holdings. 115 funds opened positions while 384 raised stakes. 589.78 million shares or 2.68% less from 606.01 million shares in 2017Q2 were reported. Manufacturers Life Ins The holds 0.23% of its portfolio in Lowe's Companies, Inc. (NYSE:LOW) for 2.46M shares. Venator Capital Management Ltd stated it has 2.82% of its portfolio in Lowe's Companies, Inc. (NYSE:LOW). Lenox Wealth Advsrs Inc stated it has 6 shares. First Allied Advisory Services holds 17,492 shares or 0.06% of its portfolio. Yorktown Mgmt And Research stated it has 0.08% of its portfolio in Lowe's Companies, Inc. (NYSE:LOW). Integral Derivatives Ltd Llc accumulated 13,890 shares. Professional Advisory Serv, Florida-based fund reported 2,745 shares. Dorsal Cap Limited Liability Co invested 3.74% of its portfolio in Lowe's Companies, Inc. (NYSE:LOW). Walleye Trading Ltd Liability accumulated 100,814 shares. Nordea Investment Mngmt Ab accumulated 548,792 shares or 0.11% of the stock. Moreover, Cutler Inv Counsel Lc has 0.06% invested in Lowe's Companies, Inc. (NYSE:LOW). Arcadia Mi, a Michigan-based fund reported 1,993 shares. New Mexico Educational Retirement Board owns 79,777 shares. Farmers & Merchants Investments has invested 1.14% in Lowe's Companies, Inc. (NYSE:LOW). Envestnet Asset Mgmt holds 0.01% or 78,063 shares.

The stock increased 5.35% or $5.12 during the last trading session, reaching $100.86. About 14.25M shares traded or 127.80% up from the average. Lowe's Companies, Inc. (NYSE:LOW) has risen 5.92% since January 16, 2017 and is uptrending. It has underperformed by 10.78% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: